The objective of the radioprotection program is to develop a radiomitigation drug, administered in the minutes / hours following an overexposure to ionizing radiation. It will be used for the treatment of civilian and military personnel (dual technology) exposed internally or externally to radiation, whether industrial, medical, accidental or intentional.

 

Nuclear radioprotection / radiomitigation drug

The context of nuclear and radiological (NR) risk within the armed forces has evolved over time.

In this context, there is currently no radiomitigative drug without major side effects: no drug incorporating molecules that, when administered after exposure to ionizing radiation at toxic/lethal dose, significantly decrease the risk of tissue damage or carcinogenesis.

The objective of the radioprotection program is to develop a radiomitigation drug, administered in the minutes / hours after an overexposure to ionizing radiation. It will be used for the treatment of civilian and military personnel (dual technology) exposed internally or externally to radiation, whether industrial, medical, accidental or intentional.

 

Our product offers significant improvements over the currently available marketed drugs:
  • Radiomitigation effect
  • Ease of administration (self-treatment)
  • Appropriate for children under the age of two years
  • No predictable toxicity
  • Anticipated stability of 3 years at room temperature
  • Ease of deployment
Share:Share on Facebook